Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Nuvation Bio Inc.
A biopharmaceutical company that develops targeted drugs for hard-to-treat cancers, Nuvation Bio makes the oral lung-cancer medicine IBTROZI (taletrectinib), approved by U.S. regulators in 2025 for patients whose non-small cell lung cancer carries a specific ROS1 gene change. It was founded in 2018 by Dr. David Hung, the same doctor behind the prostate-cancer drugmaker Medivation. The name blends "Nu-" with "-vation," a nod to innovation and to Hung's earlier Medivation success.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits